Maria Soledad Cortina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria Soledad Cortina has a total of 123 co-authors. Here are the top co-authors by number of shared publications:
Jose de la Cruz
Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois, USA
11 shared publicationsFaris I. Karas
Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL; and
6 shared publicationsJoel Sugar
Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago, IL
4 shared publications- Jose de la Cruz
UIC Department of Ophthalmology and Visual Sciences, Chicago, IL, USA
4 shared publications Ali R. Djalilian
Department of Ophthalmology, Illinois Eye and Ear Infirmary, University of Illinois, Chicago, IL; and
3 shared publications- Ali R. Djalilian
Department of Ophthalmology and Visual Sciences, University of Illinois Chicago, Chicago, IL 60612, USA
3 shared publications
Latest Publications
- Open Access
- 16 October 2026
- Published by Elsevier in The Ocular Surface
Infectious keratitis and endophthalmitis following Boston Type I keratoprosthesis: Incidence, risk factors, and long-term outcomes
- 16 October 2026
- Published by Elsevier in The Ocular Surface
Open AccessInfectious keratitis and endophthalmitis following Boston Type I keratoprosthesis: Incidence, risk factors, and long-term outcomes
- 13 October 2026
- Published by Wolters Kluwer Health in Cornea
Severe Dupilumab-Associated Ocular Surface Disease: Multicenter Experience and Management Considerations
Purpose: To evaluate severe dupilumab-associated ocular surface disease (DAOSD) and identify clinical features, risk factors, and outcomes associated with delayed ophthalmologic referral. Methods: A multicenter retrospective case series of 13 patients (26 eyes) with severe DAOSD presenting to tertiary centers between January 2014 and April 2026 was conducted. Clinical findings were analyzed alongside a focused review of current evidence on pathophysiology, diagnosis, and management. Results: Initial ocular symptoms were frequently mild and nonspecific, most commonly redness and pruritus (13/13, 100%), followed by blurred vision with tearing (3/13, 23.1%), eye pain (2/13, 15.4%), and mucoid discharge (2/13, 15.4%), contributing to delayed referral. Symptom onset ranged from 0 to 37 months after dupilumab initiation (mean 11.7 months). At presentation, advanced disease manifestations included limbitis (3/13, 23.1%), conjunctivalization with corneal neovascularization (3/13, 23.1%), limbal stem cell deficiency (2/13, 15.4%), and cicatricial conjunctivitis (1/13, 7.7%). Preexisting atopic ocular disease was present in 6/13 patients (46.2%). Management included lubrication, topical corticosteroids, calcineurin inhibitors, and scleral lenses. Dupilumab was discontinued in 7/13 patients (53.8%). Clinical stabilization was achieved in 12/13 patients (92.3%) over a mean follow-up of 21.4 ± 20.3 months. Conclusions: Severe DAOSD may be underrecognized, as mild early symptoms can delay referral and allow progression to advanced, vision-threatening complications. Preexisting ocular surface disease identifies a high-risk subgroup. Early ophthalmologic evaluation and timely referral are essential to prevent irreversible ocular surface damage and vision loss.
- 13 October 2026
- Published by Wolters Kluwer Health in Cornea
Severe Dupilumab-Associated Ocular Surface Disease: Multicenter Experience and Management Considerations
Purpose: To evaluate severe dupilumab-associated ocular surface disease (DAOSD) and identify clinical features, risk factors, and outcomes associated with delayed ophthalmologic referral. Methods: A multicenter retrospective case series of 13 patients (26 eyes) with severe DAOSD presenting to tertiary centers between January 2014 and April 2026 was conducted. Clinical findings were analyzed alongside a focused review of current evidence on pathophysiology, diagnosis, and management. Results: Initial ocular symptoms were frequently mild and nonspecific, most commonly redness and pruritus (13/13, 100%), followed by blurred vision with tearing (3/13, 23.1%), eye pain (2/13, 15.4%), and mucoid discharge (2/13, 15.4%), contributing to delayed referral. Symptom onset ranged from 0 to 37 months after dupilumab initiation (mean 11.7 months). At presentation, advanced disease manifestations included limbitis (3/13, 23.1%), conjunctivalization with corneal neovascularization (3/13, 23.1%), limbal stem cell deficiency (2/13, 15.4%), and cicatricial conjunctivitis (1/13, 7.7%). Preexisting atopic ocular disease was present in 6/13 patients (46.2%). Management included lubrication, topical corticosteroids, calcineurin inhibitors, and scleral lenses. Dupilumab was discontinued in 7/13 patients (53.8%). Clinical stabilization was achieved in 12/13 patients (92.3%) over a mean follow-up of 21.4 ± 20.3 months. Conclusions: Severe DAOSD may be underrecognized, as mild early symptoms can delay referral and allow progression to advanced, vision-threatening complications. Preexisting ocular surface disease identifies a high-risk subgroup. Early ophthalmologic evaluation and timely referral are essential to prevent irreversible ocular surface damage and vision loss.
- 17 September 2026
- Published by Elsevier in Survey of Ophthalmology
Surgical applications of expanded polytetrafluoroethylene in ophthalmology: A review
- 17 September 2026
- Published by Elsevier in Survey of Ophthalmology
Surgical applications of expanded polytetrafluoroethylene in ophthalmology: A review
- Open Access
- 14 November 2025
- Published by Elsevier in The Ocular Surface
- Vol. 38, 424-430
Recurrent retroprosthetic membranes in Boston Keratoprosthesis Type I: Incidence, risk factors, and complications
- 14 November 2025
- Published by Elsevier in The Ocular Surface
- Vol. 38, 424-430
Open AccessRecurrent retroprosthetic membranes in Boston Keratoprosthesis Type I: Incidence, risk factors, and complications
- 6 June 2025
- Published by Wolters Kluwer Health in Cornea
- Vol. 45 (3) , 338-345
Retroprosthetic Membrane Is Associated With Subsequent Development of de Novo Angle Closure in Eyes With Boston Keratoprosthesis
Purpose: Boston keratoprosthesis (KPro) is a widely used treatment for corneal diseases unsuitable for traditional keratoplasty. Postoperative complications, notably retroprosthetic membrane (RPM) formation and secondary glaucoma, significantly affect patient outcomes. Anterior segment optical coherence tomography (AS-OCT) enables precise visualization of KPro-related complications, such as angle closure and RPM formation. This study aimed to investigate the association between RPM formation and de novo angle closure in eyes with Boston KPro. Methods: A retrospective analysis of patients who underwent Boston KPro type 1 implantation was conducted. Patients with preoperative angles documented by AS-OCT and a minimum 1-year follow-up with serial AS-OCT imaging were included. Demographic data, surgical details, visual acuity, intraocular pressure, and complications were recorded. The presence of RPM and angle closure was assessed clinically and via AS-OCT. Results: This study included 18 eyes from 18 patients who underwent KPro implantation with a follow-up period averaging 4.7 years. Preoperative visual acuity was poor (20/400 or worse) in all eyes, with an improvement in 78% of cases to 20/200 or better postoperatively. Complications included angle closure in 61% of eyes, with a significant association between retroprosthetic membrane (RPM) formation and angle closure ( P = 0.0012). De novo glaucoma developed in 4 eyes, primarily associated with RPM and angle closure, and was managed medically. Conclusions: This study highlights a significant association between RPM formation and de novo angle closure in eyes with Boston KPro. Our study findings strongly suggest that RPM formation plays a role in inducing angle closure, contributing to glaucoma development, and is the first study to provide AS-OCT evidence of potential causality. Understanding these associations can improve patient care and outcomes after KPro implantation. Strategies aimed at reducing RPM formation could potentially mitigate other KPro-related complications, including angle closure and de novo glaucoma.
- 6 June 2025
- Published by Wolters Kluwer Health in Cornea
- Vol. 45 (3) , 338-345
Retroprosthetic Membrane Is Associated With Subsequent Development of de Novo Angle Closure in Eyes With Boston Keratoprosthesis
Purpose: Boston keratoprosthesis (KPro) is a widely used treatment for corneal diseases unsuitable for traditional keratoplasty. Postoperative complications, notably retroprosthetic membrane (RPM) formation and secondary glaucoma, significantly affect patient outcomes. Anterior segment optical coherence tomography (AS-OCT) enables precise visualization of KPro-related complications, such as angle closure and RPM formation. This study aimed to investigate the association between RPM formation and de novo angle closure in eyes with Boston KPro. Methods: A retrospective analysis of patients who underwent Boston KPro type 1 implantation was conducted. Patients with preoperative angles documented by AS-OCT and a minimum 1-year follow-up with serial AS-OCT imaging were included. Demographic data, surgical details, visual acuity, intraocular pressure, and complications were recorded. The presence of RPM and angle closure was assessed clinically and via AS-OCT. Results: This study included 18 eyes from 18 patients who underwent KPro implantation with a follow-up period averaging 4.7 years. Preoperative visual acuity was poor (20/400 or worse) in all eyes, with an improvement in 78% of cases to 20/200 or better postoperatively. Complications included angle closure in 61% of eyes, with a significant association between retroprosthetic membrane (RPM) formation and angle closure ( P = 0.0012). De novo glaucoma developed in 4 eyes, primarily associated with RPM and angle closure, and was managed medically. Conclusions: This study highlights a significant association between RPM formation and de novo angle closure in eyes with Boston KPro. Our study findings strongly suggest that RPM formation plays a role in inducing angle closure, contributing to glaucoma development, and is the first study to provide AS-OCT evidence of potential causality. Understanding these associations can improve patient care and outcomes after KPro implantation. Strategies aimed at reducing RPM formation could potentially mitigate other KPro-related complications, including angle closure and de novo glaucoma.
- Open Access
- 27 March 2025
- Published by Wolters Kluwer Health in Indian Journal Of Ophthalmology
- Vol. 73 (4) , 483-495
Neurotrophic keratopathy: Update in diagnosis and management
The cornea is the most densely sensory innervated tissue in the body. Sensory corneal nerves are essential to maintain ocular surface homeostasis and are involved in the blink reflex, tear production, and the release of trophic factors that are key in the wound healing process. Compromise of corneal sensory nerves leads to neurotrophic keratopathy (NK), an uncommon degenerative disorder that may lead to corneal epithelial breakdown, ulceration, corneal opacification, and even perforation. Management of this condition is difficult and visual disability often ensues in affected patients. While treatment has been traditionally focused in promoting epithelial healing, the past decade has seen a breakthrough in new medical and surgical therapies geared toward promoting corneal reinnervation. This review presents a comprehensive update on NK, focusing on current as well as potential new strategies for its diagnosis and management.
- 27 March 2025
- Published by Wolters Kluwer Health in Indian Journal Of Ophthalmology
- Vol. 73 (4) , 483-495
Open AccessNeurotrophic keratopathy: Update in diagnosis and management
The cornea is the most densely sensory innervated tissue in the body. Sensory corneal nerves are essential to maintain ocular surface homeostasis and are involved in the blink reflex, tear production, and the release of trophic factors that are key in the wound healing process. Compromise of corneal sensory nerves leads to neurotrophic keratopathy (NK), an uncommon degenerative disorder that may lead to corneal epithelial breakdown, ulceration, corneal opacification, and even perforation. Management of this condition is difficult and visual disability often ensues in affected patients. While treatment has been traditionally focused in promoting epithelial healing, the past decade has seen a breakthrough in new medical and surgical therapies geared toward promoting corneal reinnervation. This review presents a comprehensive update on NK, focusing on current as well as potential new strategies for its diagnosis and management.
- 22 January 2025
- Published by Wolters Kluwer Health in Cornea
- Vol. 44 (11) , 1333-1340
Long-Term Outcomes of Pediatric Keratoplasty at a Tertiary Care Center
Purpose: To report the indications, postoperative visual outcomes, and long-term graft survival of primary pediatric keratoplasties performed at a single tertiary care center. Methods: We conducted a retrospective review of pediatric patients (16 years and younger) who underwent surgical intervention for corneal opacity at a tertiary care center to evaluate long-term graft survival and visual rehabilitation. Results: Seventy-three eyes of 46 patients met inclusion criteria. The mean patient age at the time of transplantation was 7.44 years (range, 5 months–15.72 years), and the average follow-up time was 5.82 years. Forty eyes (56%) had graft failure occurring at a mean time of 16.33 months (range, 27 days–12.58 years), of which 25 eyes (62.5%) underwent repeat keratoplasty. Cumulative graft survival probabilities at 1, 3, 5, and 7 years after keratoplasty were 60%, 55%, 44%, and 44%, respectively. Cox proportional hazards regression analysis showed Black ethnicity [hazard ratio (HR) = 4.72; confidence interval (CI), 1.16–19.23], mixed/other ethnicity (HR = 6.67, CI, 1.58–28.16), and keratoplasty in combination with another procedure (HR = 2.88; CI, 1.35–6.15) as significant risk factors of graft failure. 47 eyes (64%) achieved ambulatory vision (20/800 or better) at the last follow-up. Age younger than 5 years at time of keratoplasty was associated with better visual outcomes in patients with congenital disease (P = 0.0017). Conclusions: Pediatric keratoplasty has a high rate of graft failure but can achieve ambulatory vision in >60% of patients. Keratoplasty outcomes are improved in non-Hispanic, White patients and when the intervention is performed alone. Younger age at time of keratoplasty for congenital conditions improves the likelihood of overall visual rehabilitation.
- 22 January 2025
- Published by Wolters Kluwer Health in Cornea
- Vol. 44 (11) , 1333-1340
Long-Term Outcomes of Pediatric Keratoplasty at a Tertiary Care Center
Purpose: To report the indications, postoperative visual outcomes, and long-term graft survival of primary pediatric keratoplasties performed at a single tertiary care center. Methods: We conducted a retrospective review of pediatric patients (16 years and younger) who underwent surgical intervention for corneal opacity at a tertiary care center to evaluate long-term graft survival and visual rehabilitation. Results: Seventy-three eyes of 46 patients met inclusion criteria. The mean patient age at the time of transplantation was 7.44 years (range, 5 months–15.72 years), and the average follow-up time was 5.82 years. Forty eyes (56%) had graft failure occurring at a mean time of 16.33 months (range, 27 days–12.58 years), of which 25 eyes (62.5%) underwent repeat keratoplasty. Cumulative graft survival probabilities at 1, 3, 5, and 7 years after keratoplasty were 60%, 55%, 44%, and 44%, respectively. Cox proportional hazards regression analysis showed Black ethnicity [hazard ratio (HR) = 4.72; confidence interval (CI), 1.16–19.23], mixed/other ethnicity (HR = 6.67, CI, 1.58–28.16), and keratoplasty in combination with another procedure (HR = 2.88; CI, 1.35–6.15) as significant risk factors of graft failure. 47 eyes (64%) achieved ambulatory vision (20/800 or better) at the last follow-up. Age younger than 5 years at time of keratoplasty was associated with better visual outcomes in patients with congenital disease (P = 0.0017). Conclusions: Pediatric keratoplasty has a high rate of graft failure but can achieve ambulatory vision in >60% of patients. Keratoplasty outcomes are improved in non-Hispanic, White patients and when the intervention is performed alone. Younger age at time of keratoplasty for congenital conditions improves the likelihood of overall visual rehabilitation.
- Open Access
- 1 August 2023
- Published by Medknow in Indian Journal Of Ophthalmology
- Vol. 71 (8) , 2930-2931
The why, what, and how of publishing a manuscript: A blend of art and science
- 1 August 2023
- Published by Medknow in Indian Journal Of Ophthalmology
- Vol. 71 (8) , 2930-2931
Open AccessThe why, what, and how of publishing a manuscript: A blend of art and science
- Open Access
- 27 March 2023
- Published by Wolters Kluwer Health in Cornea Open
- Vol. 2 (1) , e0008
Metalloproteinase-9 on the Ocular Surface of Patients With Implanted Boston Type 1 Keratoprosthesis
Purpose: The aim of this study was to characterize the presence of ocular surface inflammation, using matrix metalloproteinase-9 (MMP-9) as a marker, on the ocular surface of eyes with implanted Boston keratoprosthesis type 1 (KPro). Methods: Patients with implanted KPro at a single tertiary center were recruited to assess ocular inflammation. MMP-9 was measured using the InflammaDry test in both eyes of each patient. The non-KPro eye served as the control. Rate of positivity of MMP-9 was compared between groups. Possible associations between ocular surface inflammation and the development of postoperative complications were evaluated using univariate statistical analysis. Results: Fifty eyes from 25 patients were included. The mean age was 50 years. Noninflammatory indications for KPro were predominant among patients. Eighty-eight percent of KPro eyes had a positive test for MMP-9 while only 25% of control eyes were positive (P < 001). The most common complications were retroprosthetic membrane, epithelial defects, and sterile corneal melt. The presence of a strong positive result was associated with a higher frequency of complications (80% of eyes) compared with a faint positive test (54%) and a negative test (33%). Conclusions: The KPro device seems to increase MMP-9 levels on the ocular surface. High MMP-9 levels may be associated with higher risk of complications. MMP-9 testing can be useful to assess subclinical ocular surface inflammation with a potential role in the postoperative care of patients with KPro.
- 27 March 2023
- Published by Wolters Kluwer Health in Cornea Open
- Vol. 2 (1) , e0008
Open AccessMetalloproteinase-9 on the Ocular Surface of Patients With Implanted Boston Type 1 Keratoprosthesis
Purpose: The aim of this study was to characterize the presence of ocular surface inflammation, using matrix metalloproteinase-9 (MMP-9) as a marker, on the ocular surface of eyes with implanted Boston keratoprosthesis type 1 (KPro). Methods: Patients with implanted KPro at a single tertiary center were recruited to assess ocular inflammation. MMP-9 was measured using the InflammaDry test in both eyes of each patient. The non-KPro eye served as the control. Rate of positivity of MMP-9 was compared between groups. Possible associations between ocular surface inflammation and the development of postoperative complications were evaluated using univariate statistical analysis. Results: Fifty eyes from 25 patients were included. The mean age was 50 years. Noninflammatory indications for KPro were predominant among patients. Eighty-eight percent of KPro eyes had a positive test for MMP-9 while only 25% of control eyes were positive (P < 001). The most common complications were retroprosthetic membrane, epithelial defects, and sterile corneal melt. The presence of a strong positive result was associated with a higher frequency of complications (80% of eyes) compared with a faint positive test (54%) and a negative test (33%). Conclusions: The KPro device seems to increase MMP-9 levels on the ocular surface. High MMP-9 levels may be associated with higher risk of complications. MMP-9 testing can be useful to assess subclinical ocular surface inflammation with a potential role in the postoperative care of patients with KPro.
- Open Access
- 1 January 2023
- Published by AME Publishing Company in Annals of Eye Science
- Vol. 9
Boston type I keratoprosthesis
Review Article Boston type I keratoprosthesis Karen Hu, Imane Tarib, Maria Soledad Cortina
- 1 January 2023
- Published by AME Publishing Company in Annals of Eye Science
- Vol. 9
Open AccessBoston type I keratoprosthesis
Review Article Boston type I keratoprosthesis Karen Hu, Imane Tarib, Maria Soledad Cortina